T-cell masthead image

HyBryte™

Paper

“Visible Light Activated Topical Hypericin Ointment in CTCL: Phase 3 FLASH Study Results” presented by Ellen Kim, MD at the American Academy of Dermatology Virtual Meeting Experience April 24, 2021 (AAD 2021)

  • External Link
“Visible Light Activated Topical Hypericin Ointment in CTCL: Phase 3 FLASH Study Results” presented by Ellen Kim, MD at the American Academy of Dermatology Virtual Meeting Experience April 24, 2021 (AAD 2021)
Paper

White paper entitled, “SGX301 as a Rapid, Safe and Effective Treatment for Early Stage CTCL,” by Brian Poligone, MD, PhD; Henry Wong, MD, PhD; Aaron Mangold, MD; Jennifer DeSimone, MD; Lucia Seminario-Vidal, MD, PhD; and Ellen Kim, MD, November 13, 2020 (White Paper 2020)

  • External Link
White paper entitled, “SGX301 as a Rapid, Safe and Effective Treatment for Early Stage CTCL,” by Brian Poligone, MD, PhD; Henry Wong, MD, PhD; Aaron Mangold, MD; Jennifer DeSimone, MD; Lucia Seminario-Vidal, MD, PhD; and Ellen Kim, MD, November 13, 2020 (White Paper 2020)
Paper

“Topical Hypericin Ointment (SGX301) Photodynamic Therapy is Effective and Safe in CTCL: Results from the Multicenter Phase 3 FLASH Study” presented by Ellen

  • External Link
“Topical Hypericin Ointment (SGX301) Photodynamic Therapy is Effective and Safe in CTCL: Results from the Multicenter Phase 3 FLASH Study” presented by Ellen
Paper

“Topical Hypericin Ointment Photodynamic Therapy is Effective and Safe in CTCL (FLASH Study)” presented by Ellen Kim, MD at the Society for Investigative Dermatology (SID)Virtual Meeting May 4, 2021 (SID 2021)

  • External Link
“Topical Hypericin Ointment Photodynamic Therapy is Effective and Safe in CTCL (FLASH Study)” presented by Ellen Kim, MD at the Society for Investigative Dermatology (SID)Virtual Meeting May 4, 2021 (SID 2021)
Paper

“Phase 3 Efficacy with a Novel, First in Class, Well-Tolerated Photodynamic Therapy (HyBryte™) for Early Stage Cutaneous T-Cell Lymphoma,” to be presented by Christopher Pullion, DO at the National Organization for Rare Disorders (NORD) Breakthrough Summit, October 18-19, 2021 (NORD 2021)

  • External Link
“Phase 3 Efficacy with a Novel, First in Class, Well-Tolerated Photodynamic Therapy (HyBryte™) for Early Stage Cutaneous T-Cell Lymphoma,” to be presented by Christopher Pullion, DO at the National Organization for Rare Disorders (NORD) Breakthrough Summit, October 18-19, 2021 (NORD 2021)
Paper

“Response in a Patient with Refractory Folliculotropic Mycosis Fungoides to a Topical Hypericin Cream Activated with Fluorescent Light” presented by Brian Poligone, MD, PhD at the 4th World Congress of Cutaneous Lymphomas (WCCL) Congress, February 12-14, 2020 (WCCL 2020)

  • External Link
“Response in a Patient with Refractory Folliculotropic Mycosis Fungoides to a Topical Hypericin Cream Activated with Fluorescent Light” presented by Brian Poligone, MD, PhD at the 4th World Congress of Cutaneous Lymphomas (WCCL) Congress, February 12-14, 2020 (WCCL 2020)